Wyeth predicts quick response to Tygacil "approvable" letter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wyeth anticipates submitting a complete response to FDA's "approvable" letter for a new community-acquired pneumonia indication for its I.V. antibiotic Tygacil (tigecycline) by June 27, the company says after announcing receipt of the letter on May 29. On that timetable, the sNDA would have a user fee goal of Dec. 22. FDA requested additional analyses of the antibiotic "in patients with CAP with illness severe enough to require hospitalization, including those who are at higher risk of mortality," Wyeth says. FDA also asked for benefit/risk information on the potential for liver toxicity; Wyeth maintains that such information was presented to FDA during the review period, noting that "the agency acknowledged in its letter that it had not yet reviewed that information.
You may also be interested in...
Boehringer Ingelheim, Gubra Enter Third Obesity Deal
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
What’s Next? Five Things To Look Out For In March
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: